Technical Analysis for SESN - Sesen Bio, Inc.

Grade Last Price % Change Price Change
grade F 0.69 -8.00% -0.06
SESN closed down 8.0 percent on Thursday, January 17, 2019, on 2.45 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SESN trend table...

Date Alert Name Type % Chg
Jan 17 New 52 Week Closing Low Bearish 0.00%
Jan 17 New 52 Week Low Weakness 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Down 3 Days in a Row Weakness 0.00%
Jan 17 Oversold Stochastic Weakness 0.00%
Jan 16 New 52 Week Closing Low Bearish -8.00%
Jan 16 Narrow Range Bar Range Contraction -8.00%
Jan 16 Wide Bands Range Expansion -8.00%
Jan 16 Oversold Stochastic Weakness -8.00%
Jan 15 Inside Day Range Contraction -11.54%

Older signals for SESN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Is SESN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.5
52 Week Low 0.68
Average Volume 1,804,299
200-Day Moving Average 1.8526
50-Day Moving Average 1.3676
20-Day Moving Average 0.993
10-Day Moving Average 0.796
Average True Range 0.1306
ADX 32.52
+DI 14.435
-DI 34.6813
Chandelier Exit (Long, 3 ATRs ) 1.1582
Chandelier Exit (Short, 3 ATRs ) 1.0718
Upper Bollinger Band 1.4794
Lower Bollinger Band 0.5066
Percent B (%b) 0.19
BandWidth 97.96576
MACD Line -0.1904
MACD Signal Line -0.1741
MACD Histogram -0.0163
Fundamentals Value
Market Cap 10.62 Million
Num Shares 15.4 Million
EPS 0.11
Price-to-Earnings (P/E) Ratio 6.27
Price-to-Sales 0.56
Price-to-Book 1.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.83
Resistance 3 (R3) 0.84 0.80 0.80
Resistance 2 (R2) 0.80 0.77 0.80 0.79
Resistance 1 (R1) 0.75 0.75 0.73 0.74 0.79
Pivot Point 0.71 0.71 0.71 0.71 0.71
Support 1 (S1) 0.66 0.68 0.64 0.65 0.59
Support 2 (S2) 0.62 0.66 0.62 0.59
Support 3 (S3) 0.57 0.62 0.58
Support 4 (S4) 0.56